Global Artificial Tear Market Forecast to 2030 Featuring Analysis of J&J Vision Care, Allergan, Alcon, Bausch & Lomb, Santen, URSAPHARM Arzneimittel, and ROHTO Pharmaceutical
January 24, 2024 05:07 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Artificial Tear Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. With...
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
January 08, 2024 07:00 ET
|
OKYO Pharma LTD
Statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after dosingStatistically significant improvement was observed in both a...
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
December 04, 2023 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...
OTC Dry Eye Drops Market Size, Share & Trends Analysis Report 2023-2030: Rising Digital Screen Usage Fuels Global OTC Dry Eye Drops Market Growth
November 20, 2023 08:18 ET
|
Research and Markets
Dublin, Nov. 20, 2023 (GLOBE NEWSWIRE) -- The "OTC Dry Eye Drops Market Size, Share & Trends Analysis Report By Type (Branded, Generics), By Product Type, By Viscosity, By Distribution Channel,...
Dry Eye Treatment Devices Market Trends Analysis Report 2023-2030 with Competitive Analysis of Sight Sciences, Lumenis, ESW Vision, Johnson & Johnson, Alcon, & MiBo Medical Group
October 24, 2023 11:18 ET
|
Research and Markets
Dublin, Oct. 24, 2023 (GLOBE NEWSWIRE) -- The "Dry Eye Treatment Devices Market Size, Share & Trends Analysis Report By Technology (MGX, Combination (MGX+IPL)), By End-use (Hospitals, Ophthalmic...
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
October 05, 2023 07:00 ET
|
OKYO Pharma LTD
Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-week Phase 2 trial, with 72% of randomized DED patients completing 8 weeks, and 7.1% of patients completing the...
Growing Demand for Painless LASIK Surgeries Drives Opportunities in the Global Refractive Surgery Devices Market 2023-2030
September 28, 2023 07:13 ET
|
Research and Markets
Dublin, Sept. 28, 2023 (GLOBE NEWSWIRE) -- The "Global Refractive Surgery Devices Market by Product Type (Aberrometers, Microkeratome, Ophthalmic Laser), Application (Astigmatism, Dry Eyes,...
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
September 08, 2023 07:00 ET
|
OKYO Pharma LTD
Full enrollment achieved on September 6th with a total of 240 patients enrolled in studyTop-line data planned for release in December 2023Phase 2 trial is designed as a potential registration trial,...
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)
August 30, 2023 07:00 ET
|
OKYO Pharma LTD
Full enrollment anticipated by first week of SeptemberOKYO on schedule to release top-line data before end of 2023Phase 2 trial is designed as potential registration trial with pre-specified primary...
OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer
July 27, 2023 11:30 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease...